Review article : The endocannabinoid system and its therapeutic exploitation in multiple sclerosis : Clues for other neuroinflammatory diseases Valerio Chiurchiù, Mario van der Stelt, Diego Centonzed, Mauro Maccarrone, Progress in Neurobiology, 2018, 160 , 82–100 © 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). A B S T R A C T Multiple sclerosis is the most common inflammatory demyelinating disease of the central nervous system, caused by an autoimmune response against myelin that eventually leads to progressive neurodegeneration and disability. Although the knowledge on its underlying neurobiological mechanisms has considerably improved, there is a [...]
Lire la suiteDemystifying Cannabis Daniele Piomelli, Cannabis and Cannabinoid Research, Volume 4, Number 1, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2019.29012.edi Every new book by Malcolm Gladwell goes, by default, straight to the top of my reading list. In the unlikely event that you are not familiar with the work of this Canadian author, make time to read The Tipping Point (Little, Brown and Co., 2000) or Outliers (Little, Brown and Co., 2008), and you will see why. Not only Gladwell is remarkably well informed and clear, as one would expect from an accomplished writer and public speaker, but he also has an unusual knack for uncovering [...]
Lire la suiteLe CIRC-Lyon organise Bienvenue au Cannabistrot? ! Quelle légalisation pour demain ? avril 2019 L'OBSTINATION DES AUTORITÉS FACE À LA LUCIDITÉ DES CITOYEN(NE)S L'obstination des autorités face à la lucidité des citoyen(ne)s L'on peut penser ce que l'on veut des consultations populaire, il en est parfois révélatrice d?une prise de conscience. Ainsi les 72 % de Villeurbannais favorables à la légalisation du cannabis selon les résultats de la consultation <https://viva.villeurbanne.fr/l-essentiel/2019/mars/75-des-villeurbannais-favorables-a-une-evolution-de-la-legislation> organisée par la municipalité dans le cadre des tables-rondes auxquels les habitant(e)s étaient invité(e)s à participer, démontrent la remarquable maturité des citoyen(ne)s de la ville. Confronté(e)s comme d'autres ailleurs aux effets délétères de la prohibition (occupation de l'espace public par les réseaux [...]
Lire la suiteMedicinal Use of Synthetic Cannabinoids—a Mini Review P. Muralidhar Reddy, Nancy Maurya & Bharath Kumar Velmurugan Current Pharmacology Reports, 2019 https://doi.org/10.1007/s40495-018-0165-y Abstract Purpose of Review : This review gives an overview of the medicinal uses of synthetic cannabinoids and other related aspects on the basis of recent as well as earlier studies that the authors considered relevant to the context and scope of the review. Recent Findings Synthetic cannabinoids are laboratory synthesized products eliciting effects way more than their natural counterparts. These compounds are more potent in generating intoxicating effects and are also difficult to be detected in conventional screening tests. Their clinical side effects are also more pronounced than [...]
Lire la suiteLong-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US Tristan T. Sands, Shahryar Rahdari, Michael S. Oldham, Eduardo Caminha Nunes, Nicole Tilton & Maria Roberta Cilio CNS Drugs, 2018 DOI : 10.1007/s40263-018-0589-2 Abstract Background : Purified cannabidiol is a new antiepileptic drug that has recently been approved for use in patients with Lennox–Gastaut and Dravet syndromes, but most published studies have not extended beyond 12–16 weeks. Objective : The objective of this study was to evaluate the long-term safety, tolerability, and efficacy of cannabidiol in children with epilepsy. Methods : Patients aged 1–17 years with refractory epilepsy were enrolled in an open-label [...]
Lire la suiteNeuroprotection by cannabidiol and hypothermia in a piglet model of newborn hypoxic-ischemic brain damage Lorena Barataa, Luis Arruza, Maria-José Rodríguez, Esther Aleo, Eva Vierge, Enrique Criado, Elena Sobrino, Carlos Vargas, María Ceprián, Ana Gutiérrez-Rodríguez, William Hind, José Martínez-Orgado Neuropharmacology, 2018. https://doi.org/10.1016/j.neuropharm.2018.11.020 A B S T R A C T Objective : Hypothermia, the gold standard after a hypoxic-ischemic insult, is not beneficial in all treated newborns. Cannabidiol is neuroprotective in animal models of newborn hypoxic-ischemic encephalopathy. This study compared the relative efficacies of cannabidiol and hypothermia in newborn hypoxic-ischemic piglets and assessed whether addition of cannabidiol augments hypothermic neuroprotection. Methods : One day-old HI (carotid clamp and FiO2 10% for 20min) [...]
Lire la suiteCannabis‐based products for pediatric epilepsy : A systematic review Jesse Elliott, Deirdre DeJean, Tammy Clifford, Doug Coyle, Beth K. Potter, Becky Skidmore, Christine Alexander, Alexander E. Repetski, Vijay Shukla, Bláthnaid McCoy, George A. Wells, Epilepsia, 2018, 1-14. DOI: 10.1111/epi.14608 Summary Objective : To assess the benefits and harms of cannabis‐based products for pediatric epilepsy. Methods : We identified in this living systematic review randomized controlled trials (RCTs) and nonrandomized studies (NRSs) involving children with epilepsy treated with cannabis‐based products. We searched MEDLINE, Embase, PsycINFO, Cochrane Library, and gray literature (April 25, 2018). The primary outcome was seizure freedom; secondary outcomes were seizure frequency (total, ≥50% reduction), quality of life, sleep, status epilepticus, death, gastrointestinal adverse [...]
Lire la suiteCannabis Robert Hämmig, Ulrich W. Preuss und Michael Soyka January 2019 DOI: 10.1016/B978-3-437-23021-9.00009-6 Kernaussagen ● Die Cannabispflanze, welche die Menschheit seit Jahrtausenden begleitet, wird vi elfältig genutzt: ○ als Lieferant für Fasern zur Herstellung von Tüchern, Schnüren, Seilen und Papier, ○ als Nahrungsmittel (Samenkörner und Öl), ○ als Medizin für Mensch und Tier sowie als Genussmittel. ● Im 19. Jh. hielt Cannabis Einzug in die moderne westliche Medizin und wurde auch als „Freizeitdroge“ genutzt. Aus dieser Zeit stammen detaillierte phänomenologische Bes chreibungen der Effekte. Noch blieb aber der Wirkmechanismus völlig unklar. ● Die erste Hälfte des 20. Jh. ist das „dunkle Zeitalter“ des Cannabis, in dem das Fors chungsinteresse erlahmte. [...]
Lire la suiteCannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats Saeideh Karimi-Haghighi, Abbas Haghparast Neuroscience Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran Progress in Neuropsychopharmacology & Biological Psychiatry, 2017. http://dx.doi.org/10.1016/j.pnpbp.2017.08.022 A B S T R A C T Methamphetamine (METH) is a widely abused and a severely addictive psychostimulant. Relapse is the main cause of concern when treating addiction. It could manifest after a long period of abstinence. Previous studies showed that there is a strong connection between sleep impairment and relapse. Also, it has been reported that cannabidiol might be a potential treatment for drug craving and relapse. [...]
Lire la suiteCannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats Gracie L. Hay, Sarah J. Baracz, Nicholas A. Everett, Jessica Roberts, Priscila A. Costa, Jonathon C. Arnold, Iain S. McGregor and Jennifer L. Cornish Journal of Psychopharmacology, 2018, 32, (12), 1369-1378. DOI : 10.1177/0269881118799954 , journals.sagepub.com/home/jop Abstract Background : Methamphetamine is an addictive stimulant that can cause many adverse physical, psychological and psychosocial effects. Preliminary evidence shows cannabidiol, a non-intoxicating constituent of the cannabis plant, may have efficacy in treating opioid and nicotine dependence. However, no study has yet examined whether cannabidiol treatment might impact on methamphetamine addiction. Aims : The current study [...]
Lire la suite